PINS | Peptide News, Evidence and Market Intelligence

Featured Peptide Regulation And Market Intelligence

PINS News

FDA Hold On Biohaven Trial Puts Development Risk Back In Focus

A partial clinical hold is a reminder that regulatory execution can change the risk profile of a development-stage asset even after business-development activity.

By PINS Editorial • 1 min read

PINS News

Takeda R&D Leadership Shift Highlights Partnering Pressure Across Biotech

Takeda's planned R&D leadership transition keeps attention on large-pharma partnering strategy and how emerging science moves into scaled development.

By PINS Editorial • 1 min read

PINS News

FDA Warns Against Unapproved GLP-1 Weight Loss Products Amid Safety Concerns

The FDA has issued a public advisory cautioning consumers against using unapproved GLP-1 receptor agonist drugs marketed for weight loss, citing risks of serious adverse events and lack of proven safety and efficacy.

By PINS Editorial • 1 min read

PINS News

Reverse Mergers Keep Biotech Financing Options Open

A stronger reverse-merger market gives development-stage biotech companies another route to public capital when IPO windows are selective.

By PINS Editorial • 1 min read

Latest Articles

PINS News

Lilly-Backed Caspian Launch Adds Another Signal In Metabolic Drug Development

Kura's diabetes spinout, backed by Lilly, points to continued investor and partner interest in new mechanisms for cardiometabolic disease.

By PINS Editorial • 1 min read

PINS News

FDA CBER And CDER Appointments Add Regulatory Continuity Signal

Permanent leadership at FDA review centers matters for sponsors watching review consistency, inspection posture, and policy execution.

By PINS Editorial • 1 min read

PINS News

Solstice Financing Shows Continued Appetite For Differentiated Oncology Assets

A $225 million launch round for Solstice Oncology shows investors still fund differentiated drug programs when mechanism, licensing, and development story align.

By PINS Editorial • 1 min read

Regulation

Global peptide regulation updates, including official agency notices, approvals, shortages, policy changes, and compliance standards.

FDA Hold On Biohaven Trial Puts Development Risk Back In Focus

A partial clinical hold is a reminder that regulatory execution can change the risk profile of a development-stage asset even after business-development activity.

By PINS Editorial • 1 min read

FDA Warns Against Unapproved GLP-1 Weight Loss Products Amid Safety Concerns

By PINS Editorial • 1 min read

FDA CBER And CDER Appointments Add Regulatory Continuity Signal

Permanent leadership at FDA review centers matters for sponsors watching review consistency, inspection posture, and policy execution.

By PINS Editorial • 1 min read

FDA Glutathione Reminder Sharpens Compounding Quality Expectations

FDA's reminder about injectable glutathione sourcing reinforces that compounding quality questions extend beyond product labels into ingredient grade and intended route.

By PINS Editorial • 1 min read

Markets

Peptide market intelligence covering filings, partnerships, manufacturers, funding, pipelines, supply chains, and demand shifts.

FDA Hold On Biohaven Trial Puts Development Risk Back In Focus

A partial clinical hold is a reminder that regulatory execution can change the risk profile of a development-stage asset even after business-development activity.

By PINS Editorial • 1 min read

Takeda R&D Leadership Shift Highlights Partnering Pressure Across Biotech

Takeda's planned R&D leadership transition keeps attention on large-pharma partnering strategy and how emerging science moves into scaled development.

By PINS Editorial • 1 min read

FDA Warns Against Unapproved GLP-1 Weight Loss Products Amid Safety Concerns

By PINS Editorial • 1 min read

Reverse Mergers Keep Biotech Financing Options Open

A stronger reverse-merger market gives development-stage biotech companies another route to public capital when IPO windows are selective.

By PINS Editorial • 1 min read

Tyra Phase 2 Readout Shows How Trial Expectations Can Move Markets

Tyra's Phase 2 data underline how mid-stage trial readouts can shift valuation even when a company still sees a late-stage path.

By PINS Editorial • 1 min read

Lilly-Backed Caspian Launch Adds Another Signal In Metabolic Drug Development

Kura's diabetes spinout, backed by Lilly, points to continued investor and partner interest in new mechanisms for cardiometabolic disease.

By PINS Editorial • 1 min read

FDA CBER And CDER Appointments Add Regulatory Continuity Signal

Permanent leadership at FDA review centers matters for sponsors watching review consistency, inspection posture, and policy execution.

By PINS Editorial • 1 min read

Solstice Financing Shows Continued Appetite For Differentiated Oncology Assets

A $225 million launch round for Solstice Oncology shows investors still fund differentiated drug programs when mechanism, licensing, and development story align.

By PINS Editorial • 1 min read

Moonwalk Obesity Financing Extends The Metabolic Mechanism Race

Moonwalk's $70 million financing adds another non-incretin approach to the obesity-development map watched by peptide and cardiometabolic operators.

By PINS Editorial • 1 min read

Novartis RNA Setback Underscores Evidence Risk In Acquired Pipelines

A failed rare-disease RNA study highlights how acquired assets still carry trial, endpoint, and translational risk after major business-development deals.

By PINS Editorial • 1 min read

Pelacarsen Outcome Miss Pressures Cardiometabolic Evidence Standards

A cardiometabolic outcome miss after biomarker movement is a cautionary signal for programs trying to translate mechanism into clinical benefit.

By PINS Editorial • 1 min read

AbbVie Myeloma Readout Points To Differentiation Through Safety And Submission Strategy

AbbVie's etentamig progress shows how late-stage assets can compete through efficacy, tolerability, and submission-readiness at the same time.

By PINS Editorial • 1 min read

Enforcement

Coverage of warning letters, recalls, customs actions, seizures, sanctions screening, diversion risk, and compliance enforcement.

FDA Warns Against Unapproved GLP-1 Weight Loss Products Amid Safety Concerns

By PINS Editorial • 1 min read

FDA Glutathione Reminder Sharpens Compounding Quality Expectations

FDA's reminder about injectable glutathione sourcing reinforces that compounding quality questions extend beyond product labels into ingredient grade and intended route.

By PINS Editorial • 1 min read

Products

RUO catalog positioning, COA and SDS signals, quality language, packaging, supplier standards, and claims boundaries.

Lilly-Backed Caspian Launch Adds Another Signal In Metabolic Drug Development

Kura's diabetes spinout, backed by Lilly, points to continued investor and partner interest in new mechanisms for cardiometabolic disease.

By PINS Editorial • 1 min read

Solstice Financing Shows Continued Appetite For Differentiated Oncology Assets

A $225 million launch round for Solstice Oncology shows investors still fund differentiated drug programs when mechanism, licensing, and development story align.

By PINS Editorial • 1 min read

AbbVie Myeloma Readout Points To Differentiation Through Safety And Submission Strategy

AbbVie's etentamig progress shows how late-stage assets can compete through efficacy, tolerability, and submission-readiness at the same time.

By PINS Editorial • 1 min read

Clinical Trials

Clinical trial starts, registry updates, phases, endpoints, results, and human evidence milestones.

FDA Hold On Biohaven Trial Puts Development Risk Back In Focus

A partial clinical hold is a reminder that regulatory execution can change the risk profile of a development-stage asset even after business-development activity.

By PINS Editorial • 1 min read

Tyra Phase 2 Readout Shows How Trial Expectations Can Move Markets

Tyra's Phase 2 data underline how mid-stage trial readouts can shift valuation even when a company still sees a late-stage path.

By PINS Editorial • 1 min read

Novartis RNA Setback Underscores Evidence Risk In Acquired Pipelines

A failed rare-disease RNA study highlights how acquired assets still carry trial, endpoint, and translational risk after major business-development deals.

By PINS Editorial • 1 min read

Pelacarsen Outcome Miss Pressures Cardiometabolic Evidence Standards

A cardiometabolic outcome miss after biomarker movement is a cautionary signal for programs trying to translate mechanism into clinical benefit.

By PINS Editorial • 1 min read

AbbVie Myeloma Readout Points To Differentiation Through Safety And Submission Strategy

AbbVie's etentamig progress shows how late-stage assets can compete through efficacy, tolerability, and submission-readiness at the same time.

By PINS Editorial • 1 min read

Safety

Safety alerts, recalls, warnings, adverse-event signals, quality events, and regulatory risk.

FDA Warns Against Unapproved GLP-1 Weight Loss Products Amid Safety Concerns

By PINS Editorial • 1 min read

FDA Glutathione Reminder Sharpens Compounding Quality Expectations

FDA's reminder about injectable glutathione sourcing reinforces that compounding quality questions extend beyond product labels into ingredient grade and intended route.

By PINS Editorial • 1 min read

Research

Peer-reviewed, preprint, animal, in vitro, and translational peptide research coverage.

Takeda R&D Leadership Shift Highlights Partnering Pressure Across Biotech

Takeda's planned R&D leadership transition keeps attention on large-pharma partnering strategy and how emerging science moves into scaled development.

By PINS Editorial • 1 min read

Lilly-Backed Caspian Launch Adds Another Signal In Metabolic Drug Development

Kura's diabetes spinout, backed by Lilly, points to continued investor and partner interest in new mechanisms for cardiometabolic disease.

By PINS Editorial • 1 min read

Moonwalk Obesity Financing Extends The Metabolic Mechanism Race

Moonwalk's $70 million financing adds another non-incretin approach to the obesity-development map watched by peptide and cardiometabolic operators.

By PINS Editorial • 1 min read

Novartis RNA Setback Underscores Evidence Risk In Acquired Pipelines

A failed rare-disease RNA study highlights how acquired assets still carry trial, endpoint, and translational risk after major business-development deals.

By PINS Editorial • 1 min read

Pelacarsen Outcome Miss Pressures Cardiometabolic Evidence Standards

A cardiometabolic outcome miss after biomarker movement is a cautionary signal for programs trying to translate mechanism into clinical benefit.

By PINS Editorial • 1 min read

Compounding

Compounding policy, pharmacy practice, outsourcing facility updates, shortage dynamics, and enforcement signals.

PINS News

FDA Glutathione Reminder Sharpens Compounding Quality Expectations

FDA's reminder about injectable glutathione sourcing reinforces that compounding quality questions extend beyond product labels into ingredient grade and intended route.

By PINS Editorial • 1 min read

Latest Articles

PINS News

Lilly-Backed Caspian Launch Adds Another Signal In Metabolic Drug Development

Kura's diabetes spinout, backed by Lilly, points to continued investor and partner interest in new mechanisms for cardiometabolic disease.

By PINS Editorial • 1 min read

PINS News

FDA CBER And CDER Appointments Add Regulatory Continuity Signal

Permanent leadership at FDA review centers matters for sponsors watching review consistency, inspection posture, and policy execution.

By PINS Editorial • 1 min read

PINS News

Solstice Financing Shows Continued Appetite For Differentiated Oncology Assets

A $225 million launch round for Solstice Oncology shows investors still fund differentiated drug programs when mechanism, licensing, and development story align.

By PINS Editorial • 1 min read

PINS Global Peptide Regulation, Policy And Market News

Featured Peptide Regulation And Market Intelligence

Latest Articles

Regulation

Markets

Enforcement

Products

Clinical Trials

Safety

Research

Compounding

Latest Articles

Be the first to know